Professional Documents
Culture Documents
COLLEGE OF MEDICINE
Community project
2 year 1st group 2007
nd
Done by:
Ali Mohammed (Chairman)
Ali Khair Al-Din (Presenter)
Marwa Mahmood (Reporter)
Omar Musa’id
Safana Tahir
Zahra’a Mahmood
Zahra’a Ahmed
Lamya’a Ahmed
Vian Husain
Hiba Muthanna
CONTENTS
Abbreviations 2
Abstract 3
Acknowledgement 4
Introduction 5
Results 8
Discussion 13
Conclusion 15
Recommendations 16
References 17
Appendix 18
1
ABBREVIATIONS
2
ABSTRACT
teaching hospital during the period from the 1st of April to the 1st
of May 2007.
a percentage of 38%.
child (3%).
3
ACKNOWLEDGMENT
4
INTRODUCTION
Measles vaccine:
Measles remains a leading cause of death among young
children, despite the availability of a safe and effective vaccine for
the past 40 years. An estimated 345 000 people, the majority of
them children, died from measles in 2005 (the latest year for which
figures are available).1
Active immunization has been proved to be the more
effective technique for long term immunity.
Measles Virus Vaccine, Live, Attenuated (Dried) is prepared
in avian leucosis-free chick embryo fibroblast cultures from the
Edmondston Strain of attenuated measles virus. This vaccine is
indicated for the active immunization of children against measles
(rubeola). It does not protect against German measles (rubella).
This vaccine is recommended routinely for all children at, or as
soon as practicable after, their first birthday. If a goal of measles
elimination is adopted, a second dose of measles vaccine is
required. It is given at 4 to 6 years of age. The minimum interval
between the 2 doses should be at least 1 month.
The measles vaccine is contra-indicated in cases of any acute
illness, including febrile illness. It is also contra-indicated in cases
of allergic reaction to any component of Measles Virus Vaccine.
Adverse Reactions: Local erythema and/or swelling around
the site of injection are not uncommon and regional lymph-
adenopathy may occur rarely. Fever or mild rash, or both, may
occur 5 to 12 days after administration.
Dosage and Administration: One dose of 0.5 mL of Measles
Virus Vaccine, Live, Attenuated (Dried) S.C., in Iraq at 9 months
of age, or as soon as possible thereafter. If a goal of measles
elimination is adopted, a second dose of 0.5 mL Measles Virus
5
Vaccine is required, in Iraq it is given with MMR vaccine at 15
months of age.2
Measles disease:
The un-immunized persons are most people at risk. First sign of
infection is usually high fever which begins approximately 10 to 12
days after exposure and lasts one to seven days. During the initial stage,
the patient may develop coryza (runny nose), cough, red and watery
eyes and small white spots inside the cheeks. After several days, a rash
develops, usually on the face and upper neck. Over a period of about
three days, the rash proceeds downward, eventually reaching the hands
and feet. The disease can be transmitted by an infected individual
from four days prior to the onset of the rash to four days after the onset.
The most serious complications include blindness, encephalitis (a
dangerous infection of the brain causing inflammation), severe
diarrhoea (possibly leading to dehydration), ear infections and severe
respiratory infections such as pneumonia, which is the most common
cause of death associated with measles.
Treatment by general nutritional support and the treatment of
dehydration with oral rehydration solution are necessary. Giving
vitamin A at the time of diagnosis can help prevent eye damage and
blindness.
Aim:
To find the measles vaccine coverage rate among children
under 5 years of age in Tikrit Teaching Hospital.
Objectives:
1. Identify the proportion of children (under 5 years) immunized
by measles vaccine.
2. Clarify the possible complications after immunization with
measles vaccine.
3. Identify the frequency, type and time of vaccination against
measles.
4. Determine the children who are affected with measles disease.
6
SUBJECTS AND METHODS
7
RESULTS
From the total 100 children surveyed, there were only 62% of
them who were vaccinated with the measles vaccine, the
percentage in rural areas was 63.5% while in urban areas it was
60.5%, this is shown in table (1).
8
From the vaccinated 62 children, 30 were males and 32 were
females, while the un-vaccinated 38 children were divided as 20
males and 18 females, this is shown in table (3).
Total 62 38 100
Urban Rural
Gender Immunized Unimmunized Immunized Unimmunized
Males 15(52%) 14(74%) 15(45%) 6(32%)
Females 14(48%) 5(26%) 18(55%) 13(68%)
Total 29 19 33 19
9
From the 62 immunized children, 33 children suffered
complications of the vaccine including 14 males and 19 females,
while the other 29 children didn’t have the complications including
16 males and 13 females, this is shown in table (5).
Fever 11 15 26(78%)
Others 1 4 5(16%)
Total 14 19 33
10
Most of the children who were vaccinated with measles
vaccine were also vaccinated with MMR vaccine (71%). The
reverse is also true in that most of the children who were not
vaccinated with measles vaccine also didn’t receive an MMR
vaccine (84%), this is shown in table (7).
Measles vaccine
MMR vaccine Total
Immunized Unimmunized
M:20 M:3
Immunized 44(71%) 6(16%) 50
F:24 F:3
M:10 M:17
Unimmunized 18(29%) 32(84%) 50
F:8 F:15
Total 62(100%) 38(100%) 100
11
Table (8): Frequency of vaccination with measles and MMR
vaccine.
Females 9 23 8 22
12
DISCUSSION
13
urban area was 83.8% among children under 5 years old, with only
55% for children living in rural areas.5
As shown in table(2) the causes of the un-immunization were
negligence (15%), ignorance (8%), security issue -parents didn’t
trust the vaccine-(8%), residence -living at distant places- (3%)
and disease of the child (3%).
From the 62 children vaccinated with measles vaccine, 33
children suffered from the complications of the vaccine including
57.5% females with 42.5% males (table5), and this was the same
finding in another study conducted in Egypt in 2001, that the girls
are more likely to develop complications of this vaccine.6
From the 17 cases of measles, 11 were not vaccinated with
the measles vaccine and 6 were vaccinated with it (table9), which
demonstrates that this vaccine had a good effectiveness.
14
CONCLUSION
15
RECOMMENDATIONS
To parents:
To IMoH:
16
REFERENCES
17
APPENDIX
Figure(1): The relation between gender and immunization status
with the residence of the child.
100%
26
55 48 80%
68 60%
74 40%
45 52 20%
32
0%
unimmunized
immunized
unimmunized
immunized
Urban
Rural
Urban
Rural
Males Females
80
60
Pe rce ntage 40 78
20
16 6 S1
0
Others Loss of Fever
appetite
Type of complications
18